Short answer: most people researching retatrutide in Canada make the same handful of mistakes, and almost none of them happen at the lab bench. They happen earlier: misreading a headline number, trusting a certificate that was never tested on their batch, or paying for 10 mg and receiving 6. Below are the ten we see most often, what each one costs you, and how to avoid it. Mistake #4 is the one that wastes the most money. Mistake #10 is the one nobody wants to hear.
You have probably seen the number already. Seventy pounds. Twenty-eight percent of body weight. It is the most talked-about result in metabolic research since tirzepatide, and it has created a gold rush of sellers, forum threads and TikTok videos. Most of them leave out the parts that matter.
This guide is the version we wish existed when we started stocking retatrutide. It is long because the mistakes are specific. Skim the list above if you are in a hurry, but read #4 and #10 in full.
Mistake #1: Believing “28%” is what you will see
The headline figure comes from TRIUMPH-1, the 80-week phase 3 trial Eli Lilly reported in May 2026. At the highest dose (12 mg), average weight loss was 28.3%. That number is real. It is also an average, and averages hide a lot.
Look at how results were actually spread out at the top dose:
| Weight lost (TRIUMPH-1, 12 mg, 80 weeks) | Share of participants |
|---|---|
| 25% or more | 62.5% |
| 30% or more | 45.3% |
| 35% or more | 27.2% |
Read that the other way around: more than a third of people on the highest dose did not reach 25%. Some lost far more than average, some lost far less. And these were 2,339 carefully screened adults with an average starting weight of 112.7 kg, followed by clinicians for 80 weeks, on a pharmaceutical product made under GMP conditions.
Key takeaway: the 28% figure describes a group, not a person. Anyone quoting it as a promise is selling something.
Mistake #2: Quoting the wrong statistic
Here is a detail almost no seller mentions. Lilly reports every result two ways, and the gap between them is large.
- Efficacy estimand: what happened to people who stayed on the drug as planned. This is the bigger number (28.3% at 12 mg).
- Treatment-regimen estimand: what happened to everyone randomized, including those who stopped early or missed doses. This is closer to real life (25.0% at 12 mg).
| TRIUMPH-1, 80 weeks | Efficacy estimand | Treatment-regimen estimand |
|---|---|---|
| 4 mg | −19.0% | −17.6% |
| 9 mg | −25.9% | −23.7% |
| 12 mg | −28.3% | −25.0% |
| Placebo | −2.2% | −3.9% |
In the smaller TRIUMPH-4 trial (knee osteoarthritis, 68 weeks), the gap was even wider: 28.7% versus 23.7% at 12 mg. Neither number is “wrong.” But if you are comparing retatrutide with tirzepatide or semaglutide, make sure you compare the same estimand, or the comparison is meaningless. We break down the full head-to-head in Retatrutide vs Tirzepatide vs Semaglutide.
Mistake #3: Ignoring the side effects that make people quit
Forums love the weight-loss numbers and skip the adverse-event table. That table is where the real story is. Here is what TRIUMPH-1 reported:
| Adverse event | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhea | 25.2% | 34.1% | 32.0% | 13.5% |
| Constipation | 23.8% | 25.9% | 26.1% | 10.9% |
| Vomiting | 10.6% | 22.8% | 25.3% | 4.8% |
| Dysesthesia | 5.1% | 12.3% | 12.5% | 0.9% |
| Stopped due to side effects | 4.1% | 6.9% | 11.3% | 4.9% |
Two things stand out. First, roughly one in four participants on the top dose vomited at some point. Second, there is a side effect you will not see in semaglutide or tirzepatide trials at anything like this rate: dysesthesia, an abnormal skin sensation such as tingling, burning or sensitivity to touch. In TRIUMPH-4 it reached 20.9% at 12 mg. Lilly describes these events as generally mild and rarely leading to discontinuation, but the mechanism is not yet explained.
Want the full picture, including heart rate and what is still unknown? Read our complete retatrutide safety analysis.
Mistake #4: Paying per vial instead of per verified milligram
This is the expensive one. Retatrutide is a 39-amino-acid peptide with a fatty-acid side chain, which makes it one of the costlier peptides to synthesize correctly. That cost creates a powerful incentive to cut corners, and the easiest corner to cut is the amount in the vial.
A vial labelled 10 mg can be 99% pure and still contain 6 mg. Purity tells you what fraction of the powder is the right molecule. It says nothing about how much powder there is. So the “cheap” vial at a lower sticker price can easily cost you more per real milligram than the one that looked expensive.
Run the numbers yourself before you compare suppliers:
| Vial A | Vial B | |
|---|---|---|
| Label | 10 mg | 10 mg |
| Price | $90 | $130 |
| Measured content (from COA) | 6.1 mg | 10.2 mg |
| Real cost per mg | $14.75 | $12.75 |
Illustrative example, not specific suppliers. The “cheap” vial is 16% more expensive per milligram, and any research results built on it are wrong by 40%.
Rule of thumb: if a supplier’s COA reports purity but not measured content (sometimes called net peptide content or quantity), you have no way to know what you paid for.
Mistake #5: Trusting a COA that isn’t yours
Almost every seller now posts a Certificate of Analysis. That has made COAs less useful, not more, because a single good certificate can be recycled for years. Before you trust one, check five things:
- Lot number matches your vial. A COA for a different batch tells you nothing about yours.
- Identity by mass spectrometry. HPLC shows purity. Only MS (or LC-MS) confirms the molecule is actually retatrutide and not a cheaper GLP-1 analogue.
- Measured content. See mistake #4.
- A real, named lab. You should be able to find the lab and, ideally, verify the report with them.
- A recent date. A 2024 certificate on a 2026 product is a red flag.
You can see how we publish ours in the TrueLabs COA library. For a broader checklist, read how to choose a research peptide supplier in Canada.
Mistake #6: Ordering from overseas to save $30
International sellers often look cheaper on the product page. The real comparison includes everything that happens after you click “buy.”
| Overseas seller | Canadian domestic supplier | |
|---|---|---|
| Delivery time | 2–6 weeks | 2–4 business days |
| Crosses the border | Yes, CBSA inspection | No |
| Seizure risk | Real, and you lose the money | None |
| Time in uncontrolled heat | Weeks | Days |
| Recourse if something is wrong | Very limited | Canadian business, CAD pricing |
One seized parcel wipes out the savings of several orders. TrueLabs ships from inside Canada, so parcels never touch customs.
Mistake #7: Ruining it before the vial is opened
Lyophilized (freeze-dried) peptides are fairly stable, but “fairly” is doing a lot of work. The common ways people degrade a vial before they ever use it:
- Leaving it in a hot mailbox or car. Heat is the main enemy of peptide stability. Bring parcels in promptly.
- Storing it at room temperature for months. For long-term storage, −20 °C. Short term, 2–8 °C in the fridge.
- Exposing it to light and moisture. Keep vials in their box, sealed, away from the fridge door where temperature swings.
- Repeated freeze-thaw cycles after reconstitution, which break peptides down.
Our laboratory guide to peptide reconstitution and storage covers the bench side in detail, including why bacteriostatic water is the standard diluent.
Mistake #8: Mixing up the names
Retatrutide goes by a confusing number of names online, and some sellers exploit that confusion.
- LY3437943 is Lilly’s development code. Same molecule.
- “GLP-3” is slang, not a real drug class. There is no “GLP-3 hormone.” The nickname comes from retatrutide hitting three receptors (GIP, GLP-1 and glucagon).
- “RT3”, “Reta”, “GLP-3RT” are shorthand used by research suppliers, including us, so the name fits on a label.
- Tirzepatide is a different molecule (two receptors, not three). Semaglutide is different again (one receptor).
The danger is not the nickname itself. It is that a vial labelled with an ambiguous name could contain anything. Once again, only mass spectrometry tells you which molecule you have. If you are new to the three compounds, start with our tirzepatide explainer and the three-way comparison.
Mistake #9: Assuming phase 3 means approved
Retatrutide has now succeeded in several phase 3 trials (TRIUMPH-1, TRIUMPH-4 and TRANSCEND-T2D-1). That is a huge milestone. It is not approval.
- As of October 2026, retatrutide is not approved by Health Canada or the US FDA for any use.
- Most phase 3 results so far are company-reported toplines. Full peer-reviewed publications for the main obesity trial are still coming.
- Health Canada has issued advisories about unauthorized injectable products, including GLP-1-type compounds, sold to consumers online.
- Approved alternatives exist today: semaglutide and tirzepatide can both be prescribed in Canada.
Research-grade retatrutide is sold in Canada as a laboratory chemical, labelled not for human or veterinary use. That label is not a technicality. The trial safety data you read about was generated with Lilly’s pharmaceutical product under medical supervision. It does not automatically apply to any vial bought online, from anyone, including us.
Mistake #10: Thinking the results are permanent
This is the mistake nobody wants to hear about, and the one with the best data behind it.
Retatrutide-specific withdrawal data has not been published yet. But we have very good data from its two closest relatives, and it points in one direction:
- Semaglutide (STEP 1 extension): one year after stopping, participants had regained about two-thirds of the weight they had lost.
- Tirzepatide (SURMOUNT-4): participants switched to placebo after 36 weeks regained a substantial share of their weight over the following year, while those who continued kept losing.
The researchers’ conclusion in both cases was the same: these compounds act on appetite and metabolic signalling while they are present. They do not permanently reset body weight. There is no strong reason to expect retatrutide to behave differently, and anyone claiming otherwise is ahead of the evidence.
If you personally want to lose weight: that is a conversation for a doctor, not a research supplier. Prescription options exist in Canada, and ongoing retatrutide trials are listed on ClinicalTrials.gov. Both routes come with medical monitoring that no online vial can.
The short version
| Mistake | What it costs you | The fix |
|---|---|---|
| Believing the average | Unrealistic expectations | Look at the responder spread |
| Wrong statistic | Bad comparisons | Same estimand, every time |
| Skipping the AE table | Surprises | Read the side-effect data |
| Price per vial | Up to 40% of your money | Price per measured mg |
| Recycled COA | Unknown product | Lot-matched, MS-confirmed |
| Overseas order | Seizures, heat, delays | Domestic supplier |
| Poor storage | Degraded peptide | Cold, dark, dry |
| Name confusion | Wrong molecule | Mass spec identity |
| “Phase 3 = approved” | False sense of safety | Know the regulatory status |
| “Results are permanent” | Disappointment | Read the withdrawal data |
See TrueLabs retatrutide (RT3) and its COA →
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
How much weight did people lose on retatrutide in phase 3?
In TRIUMPH-1, average weight loss at 80 weeks was 19.0%, 25.9% and 28.3% at the 4, 9 and 12 mg doses (efficacy estimand), versus 2.2% on placebo. Using the treatment-regimen estimand, the 12 mg figure was 25.0%.
What is the most common side effect of retatrutide?
Nausea, reported by 42.4% of participants on 12 mg in TRIUMPH-1, followed by diarrhea, constipation and vomiting. Dysesthesia, an abnormal skin sensation, was also reported more often than with other drugs in its class.
Is retatrutide approved in Canada?
No. As of October 2026 it is investigational and not approved by Health Canada or the FDA. Research-grade retatrutide is sold in Canada for laboratory use only.
Is retatrutide the same as GLP-3?
“GLP-3” is an informal nickname, not a real hormone or drug class. It refers to retatrutide’s action on three receptors: GIP, GLP-1 and glucagon.
Do you regain weight after stopping retatrutide?
Retatrutide withdrawal data is not yet published, but trials of semaglutide and tirzepatide showed substantial weight regain after stopping, and researchers expect a similar pattern.
How do I know a retatrutide vial is real?
Ask for a lot-matched Certificate of Analysis that includes mass spectrometry identity confirmation and measured content, from a named laboratory, dated recently.
Related reading
- Is retatrutide safe? What the trials actually show
- Retatrutide vs tirzepatide vs semaglutide
- Tirzepatide explained: what SURMOUNT and SURPASS showed
References
- Eli Lilly and Company. Retatrutide TRIUMPH-1 topline results. Press release, May 21, 2026. Lilly
- Eli Lilly and Company. Retatrutide TRIUMPH-4 topline results. Press release, December 11, 2025. Lilly
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514–526. PubMed
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. PubMed
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. PubMed
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use, and nothing in this article is medical advice or a recommendation to use any compound. If you are considering weight-loss treatment, please talk to a doctor.